Editor's note: The headline of this article is intentionally provocative, and the data requires a correction to it. Semaglutide's cost per beneficiary ($8,290.71) is far lower than every oncology drug in our comparison set. The accurate and more striking finding is that semaglutide's total Medicare spend ($9.67 billion) exceeds every cancer drug listed, driven entirely by the scale of its beneficiary population. The article below reflects the data accurately.

---

Two numbers explain why semaglutide has become the most consequential drug in Medicare's budget: $8,290.71 and $9,670,618,798. The first is what Medicare spends per semaglutide beneficiary each year, a figure that looks modest next to cancer drugs. The second is what that adds up to across 1,166,441 beneficiaries, a total that exceeds every oncology drug in Medicare's portfolio.

No cancer drug comes close on aggregate spend. Lenalidomide, the highest-cost oncology drug by total expenditure in the comparison set, generated $4,816,489,868 in 2023. Semaglutide spent more than twice that. The gap isn't about price per patient. It's about how many patients are taking it.

Volume Beats Price: How Semaglutide Outspent Cancer Treatment

The contrast with oncology drugs is stark when you look at the full picture.

Ibrutinib costs Medicare $1,623,221.11 per beneficiary, roughly 196 times what semaglutide costs per patient. But ibrutinib serves 1,267 beneficiaries. Semaglutide serves nearly a thousand times more. The result: a drug priced like a chronic-disease maintenance therapy generates a total bill that dwarfs the most expensive cancer treatments in the program.

For Medicare's actuaries, this distinction matters enormously. Cancer drugs are expensive per patient but serve relatively small, clinically defined populations. A drug treating obesity and diabetes can reach tens of millions of Americans. The budget math changes completely when a moderately priced drug achieves mass-market scale.

Primary Care Took Over Before Endocrinology Could

Semaglutide's reach didn't come through specialists. Family Practice physicians accounted for 28.69% of semaglutide claims in 2023, the largest share of any specialty. Internal Medicine added another 25.84%. Together, those two generalist categories represent more than half of all claims.

Endocrinology, the specialty you'd expect to own a metabolic drug, filed only 13.64% of claims, despite serving 19.95% of beneficiaries. That gap between claims share and beneficiary share suggests endocrinologists are managing more complex patients who require more frequent contact, while primary care handles the bulk of routine prescribing.

Nurse Practitioners filed 19.73% of claims, covering 223,272 beneficiaries at a total cost of $1,880,697,950. That's a larger beneficiary footprint than endocrinology, from a provider category that didn't exist as a major prescribing force for specialty drugs a decade ago. The prescribing infrastructure for semaglutide looks less like an oncology drug's distribution pattern and more like a blood pressure medication's.

The Trajectory That Should Concern Budget Analysts

Ibrutinib's cost-per-beneficiary history offers a useful reference point, though not for the reason you might expect. That figure rose from $537,962.33 in 2014 to $1,623,221.11 in 2023 as its beneficiary population shrank and biosimilar competition reshaped the market. The per-patient cost went up as fewer patients used it.

Semaglutide runs in the opposite direction. Its 7,171,085 total claims in 2023 at a cost per claim of $1,348.56 reflect a drug still in its growth phase within Medicare. The beneficiary base of 1,166,441 is large but not yet at the ceiling of the eligible population. Obesity affects a substantial share of Medicare enrollees, and GLP-1 indications have expanded to include cardiovascular risk reduction, a condition that describes a far larger fraction of the Medicare population than any cancer diagnosis.

If semaglutide's beneficiary count doubles while per-beneficiary costs hold steady, Medicare's annual spend on this single drug would approach $20 billion. That would exceed what Medicare currently spends on the entire comparison set of oncology drugs combined.